Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Beyang Therapeutics closes an oversubscribed Series A financing round, raising nearly $30 million to accelerate its AI-driven ExCEED platform's development. The round was co-led by Legend Capital and Shanghai Healthcare Capital.
PRIVATEAug 12, 2026•about 2 hours ago
Amount Raised
$30 Million
Round Type
Series A
ChengduBiotechnologyArtificial IntelligenceTherapeuticsInvestors
Yuan Bio Venture CapitalRoot Venture PartnersHarbor & Canton CapitalShanghai Sci Tech Innovation Center CapitalFenglei CapitalChina Medical System Holdings LimitedShanghai Healthcare CapitalLegend Capital
Description
Beyang Therapeutics Co., Ltd. has successfully closed an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Capital and Shanghai Healthcare Capital, with support from existing investors. The proceeds will be utilized to enhance the technological capabilities of the ExCEED platform and expand international R&D teams
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech